Sep 17, 2025 1:00am EDT Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
Sep 10, 2025 8:00am EDT Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
Aug 13, 2025 5:00pm EDT Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Jul 08, 2025 8:00am EDT Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
May 14, 2025 9:00am EDT Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Apr 15, 2025 8:30am EDT Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Mar 27, 2025 8:00am EDT BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
Mar 17, 2025 4:16pm EDT Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
Mar 04, 2025 8:03am EST Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
Feb 25, 2025 7:58am EST Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
